Please ensure Javascript is enabled for purposes of website accessibility

Why Invitae Skyrocketed 20.5% Today

By Todd Campbell - Updated Mar 25, 2020 at 4:52PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A widespread stock market rally sent shares in the genetic screening company higher.

What happened

Invitae's (NVTA -3.63%) shares soared 20.5% on Wednesday as bargain-hunters and short covering converged to send the iShares Russell 2000 Index ETF (IWM -1.77%) index 1.9% higher today.

So what

Global stock markets have tumbled on fear that social distancing and sheltering in place is causing a significant slowdown in economic activity. The iShares Russell 2000 Index ETF has lost almost 40% of its value in 2020, and Invitae, which is a member of that index, was down roughly 25% year-to-date through Tuesday's close.

A person looking at a double-helix DNA strand.

IMAGE SOURCE: GETTY IMAGES.

On Wednesday, investor optimism that U.S. federal government stimulus package will ease the rate of decline in gross domestic product sparked a rally, forcing short sellers to cover bets on falling prices and prompting investors to reconsider the outlook for growth stocks like Invitae, a healthcare company that provides neonatal and cancer genetic screening to parents and patients. 

As of March 13, over 22 million shares, or 25.7% of Invitae's shares available for trading were held short, despite the fact that the company generated revenue of $216.8 million in 2019, up 47% from 2018.

Now what

Invitae's goal is to reduce its cost per test to levels that allow it to provide genetic screening to everybody. In 2019, it cost the company just $245 per sample on average to perform a test, down 7% year over year. For perspective, it performed just 150,000 tests at an average cost of $335 per test in 2017.

In 2020, the company's guidance is to perform over 725,000 tests, generating over $330 million in sales. If it can deliver on its revenue outlook, it would represent top-line growth of more than 50%. The outlook is encouraging, but investors should realize management is reinvesting heavily back into its business to gain widespread use of its tests. As a result, its operating costs were $461 million last year, resulting in a net loss of $242 million. 

 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Invitae Stock Quote
Invitae
NVTA
$2.52 (-3.63%) $0.10
iShares Trust - iShares Russell 2000 ETF Stock Quote
iShares Trust - iShares Russell 2000 ETF
IWM
$169.38 (-1.77%) $-3.06

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
319%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/29/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.